Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1467755

The outcomes of neoadjuvant immunotherapy combined with chemotherapy in pulmonary sarcomatoid carcinoma：case series and literature review

Provisionally accepted
Xiaokang Guo Xiaokang Guo 1,2Jingjing Wang Jingjing Wang 2*Daosheng Li Daosheng Li 3*Bin Wang Bin Wang 4*HUI ZHUI HUI ZHUI 2Hongbo Guo Hongbo Guo 2*
  • 1 Other, Jinan, China
  • 2 Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong Province, China
  • 3 the Afliated Taian City Central Hospital of Qingdao University, Taian, China
  • 4 Changyi People’s Hospital, Weifang, Shandong Province, China

The final, formatted version of the article will be published soon.

    Background：Pulmonary sarcomatoid carcinoma (PSC) is a highly aggressive malignancy with a significant risk of recurrence even after surgical intervention, leading to a dismal prognosis. In recent years, perioperative immunotherapy has demonstrated promising results in resectable non-small cell lung cancer (NSCLC). However, there is a lack of studies reporting the efficacy of perioperative immunotherapy in PSC.We report the clinical outcomes of four patients diagnosed with locally advanced PSC who underwent neoadjuvant immunotherapy in combination with chemotherapy from 2021 to 2023 in our hospital. Prior to surgery, these patients received 2 to 4 cycles of neoadjuvant treatment. Post-treatment imaging assessments indicated a partial response (PR) in all cases, and each patient successfully achieved R0 resection. Pathological evaluations demonstrated significant pathological responses: one patient attained Pathological Complete Response (PCR), two patients exhibited Major Pathological Response (MPR), and one patient showed PR. Currently, all four patients remain alive without evidence of tumor progression. Notably, the patient who achieved PCR has maintained a disease-free survival (DFS) exceeding 32 months post-surgery, while their event-free survival (EFS) has surpassed 36 months.Neoadjuvant immunotherapy in combination with chemotherapy has provided new promise for the treatment of locally advanced PSC with surgical potential. But these findings still need to be verified by further prospective researches

    Keywords: case report1, pulmonary sarcomatoid carcinoma 2, immunotherapy 3, targeted therapy 4, biomarkers 5

    Received: 20 Jul 2024; Accepted: 08 Nov 2024.

    Copyright: © 2024 Guo, Wang, Li, Wang, ZHUI and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jingjing Wang, Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong Province, China
    Daosheng Li, the Afliated Taian City Central Hospital of Qingdao University, Taian, China
    Bin Wang, Changyi People’s Hospital, Weifang, Shandong Province, China
    Hongbo Guo, Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.